References
- Fishman J., Goldberg S., Rosenfeld R. S., et al. Intermediates in the transformation of oral estradiol. J Clin Endocrinol Metab 1969; 29: 41–6
- Adlercreutz H., Luukkainen T. Biochemical and clinical aspects of the enterohepatic circulation of oestrogens. Acta Endocrinol (Copenh) 1967; 124(Suppl)101–40
- Purdy R. H., Engel L. L., Oncley J. L. The characterization of estrone sulfate from human plasma. J Biol Chem 1961; 236: 1043–50
- Smith O. W., Hagerman D. D. Quantitative estimation of estrogen conjugates in late pregnancy plasma. J Clin Endocrinol Metab 1965; 25: 732–41
- Rosenthal H. E., Pietrzak E., Slaunwhite W. R., et al. Binding of estrone sulfate in human plasma. J Clin Endocrinol Metab 1972; 34: 805–13
- Pan C. C., Woolever C. A., Bhavnani B. R. Transport of conjugated and unconjugated equine estrogens with human serum proteins. J Clin Endocrinol Metab 1985; 61: 499–507
- Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas. 1990; 12: 171–97
- Englund D. E., Johansson EDB. Plasma levels of oestrone, oestradiol and gonadotrophins in postmenopausal women after oral and vaginal administration of conjugated equine oestrogens (Premarin). Br J Obstet Gynaecol. 1978; 85: 957–64
- Bhavnani B. R., Sarda I. R., Woolever C. A. Radioimmunoassay of plasma equilin and estrone in postmenopausal women after the administration of Premarin. J Clin Endocrinol Metab 1981; 52: 741–7
- FDA, Office of Generic Drugs. Guidance on Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design. Washington, DC: FDA, 1. July, 1992
- Troy S. M., Hicks D. R., Parker V. D., et al. Differences in pharmacokinetics and comparative bioavailability between Premarin and Estratab in healthy postmenopausal women. Curr Tber Res 1994; 55: 359–72
- Baracat E., Haidar M., Peloso U., et al. Activity and tissue selectivity of Δ8–9-dehydroestrone sulfate in postmenopausal women. Menopause 1996; 3: 250–1